

# CECRI deaminates Ade-Rib to Ino

D'Eustachio, P., Jassal, B.

European Bioinformatics Institute, New York University Langone Medical Center, Ontario Institute for Cancer Research, Oregon Health and Science University.

The contents of this document may be freely copied and distributed in any media, provided the authors, plus the institutions, are credited, as stated under the terms of [Creative Commons Attribution 4.0 International \(CC BY 4.0\) License](#). For more information see our [license](#).

19/05/2024

## Introduction

Reactome is open-source, open access, manually curated and peer-reviewed pathway database. Pathway annotations are authored by expert biologists, in collaboration with Reactome editorial staff and cross-referenced to many bioinformatics databases. A system of evidence tracking ensures that all assertions are backed up by the primary literature. Reactome is used by clinicians, geneticists, genomics researchers, and molecular biologists to interpret the results of high-throughput experimental studies, by bioinformaticians seeking to develop novel algorithms for mining knowledge from genomic studies, and by systems biologists building predictive models of normal and disease variant pathways.

The development of Reactome is supported by grants from the US National Institutes of Health (P41 HG003751), University of Toronto (CFREF Medicine by Design), European Union (EU STRP, EMI-CD), and the European Molecular Biology Laboratory (EBI Industry program).

## Literature references

- Fabregat, A., Sidiropoulos, K., Viteri, G., Forner, O., Marin-Garcia, P., Arnau, V. et al. (2017). Reactome pathway analysis: a high-performance in-memory approach. *BMC bioinformatics*, 18, 142. [↗](#)
- Sidiropoulos, K., Viteri, G., Sevilla, C., Jupe, S., Webber, M., Orlic-Milacic, M. et al. (2017). Reactome enhanced pathway visualization. *Bioinformatics*, 33, 3461-3467. [↗](#)
- Fabregat, A., Jupe, S., Matthews, L., Sidiropoulos, K., Gillespie, M., Garapati, P. et al. (2018). The Reactome Pathway Knowledgebase. *Nucleic Acids Res*, 46, D649-D655. [↗](#)
- Fabregat, A., Korninger, F., Viteri, G., Sidiropoulos, K., Marin-Garcia, P., Ping, P. et al. (2018). Reactome graph database: Efficient access to complex pathway data. *PLoS computational biology*, 14, e1005968. [↗](#)

Reactome database release: 88


This document contains 1 reaction ([see Table of Contents](#))

## CECRI deaminates Ade-Rib to Ino [↗](#)

**Stable identifier:** R-HSA-5693346

**Type:** transition

**Compartments:** extracellular region



Adenosine deaminase (CECRI, ADA2) degrades extracellular adenosine (Ade-Rib), a signaling molecule that controls a variety of cellular responses (Zavialov & Engstrom 2005). Extracellular adenosine can bind and activate four adenosine receptors (ADRs), triggering multiple intracellular processes leading to either cell activation or in suppression of cell function and cell death. ADA2 (and ADA1) decrease the local concentration of adenosine by catalysing the deamination of adenosine to inosine (Ino). ADA2 is dimeric, binding one Zn<sup>2+</sup> ion per subunit (Zavialov et al. 2010).

### Literature references

Engström, A., Zavialov, AV. (2005). Human ADA2 belongs to a new family of growth factors with adenosine deaminase activity. *Biochem. J.*, 391, 51-7. [↗](#)

Yu, X., Lauvau, G., Zavialov, AV., Spillmann, D., Zavialov, AV. (2010). Structural basis for the growth factor activity of human adenosine deaminase ADA2. *J. Biol. Chem.*, 285, 12367-77. [↗](#)

### Editions

2015-05-15	Authored, Edited	Jassal, B.
2015-06-26	Reviewed	D'Eustachio, P.